Nanobiotix soars on final talks for cancer therapy development contract

Nanobiotix SA

05/05/2023 18:33

(Updates)
    ** U.S.-listed shares of France-based drug developer Nanobiotix SA  NBTX.O  more than triple
to $6.73 - highest percentage gainer across all U.S. stock exchanges 
    ** Shares hit their highest in more than a year, and will see their best daily pct rise on
record if gains hold 
    ** Nanobiotix says it is entering into final contract negotiations following a non-binding
agreement for its experimental cancer therapy, NBTXR3, with a "major global pharmaceutical
company"
    ** The deal is for development and commercialization of NBTXR3, which is the co's lead
product candidate and is being tested for treating a type of head and neck cancer 
    ** Co adds it does not plan to make additional statements on contract negotiations until "it
is appropriate to do so, or a final definitive agreement has been signed"
    ** Including session's gains, U.S.-listed Nanobiotix shares up ~83% this year 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))